12:00 AM
Sep 08, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FX06MRI: Phase II data

The double-blind, European Phase II FIRE trial in 234 patients with AMI showed that 400 mg of IV FX06 given at the time of reperfusion missed the primary endpoint. The median left ventricular area affected by ischemia was non-significantly reduced...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >